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Background: About 20% of familial amyotrophic lateral sclerosis (ALS) is caused by mutations in
SOD1 and is typically transmitted as an autosomal dominant trait. However, due to reduced mu-
tation penetrance, the disease may present in a recessive or sporadic manner.
Objective: To determine the factors responsible for the low penetrance of the SOD1 mutation.
Methods: Twelve members of a Canadian ALS family of Filipino origin were recruited for the
study. SOD1 was sequenced in the proband. SOD1 expression was assessed by real-time-PCR
and immunoblotting.
Results: The proband was a homozygous carrier of a novel 6 bp deletion in exon 2 (G27/P28), the
pathologic significance of which was confirmed by immunohistochemistry. Eight living family
members are heterozygotes and remain unaffected at ages ranging between 48 and 85 years.
Haplotype analysis showed that the deletion is a single founder mutation likely common in the
Cagayan province (Philippines). The low penetrance of the mutation is explained by the fact that it
enhances the naturally occurring alternative splicing of exon 2 of the SOD1 mRNA, leading to
reduced transcription of the mutant allele. Indeed, Western blot analysis demonstrated the low
level of SOD1 protein in carriers of the G27/P28 compared to wild-type individuals or a carrier
of the A4V SOD1 mutation.
Conclusion: The enhanced splicing of exon 2 acts as a natural knock-down of the mutant SOD1
allele in the Filipino amyotrophic lateral sclerosis (ALS) family. There is a need for careful investi-
gation of splicing isoforms of SOD1 and other ALS genes as factors influencing the severity of
disease. Neurology® 2009;72:1153–1159
GLOSSARY
AD  Alzheimer disease; ALS  amyotrophic lateral sclerosis; CBD  corticobasal syndrome; HCI  hyaline conglomerate
inclusions; RT-PCR  reverse transcriptase–polymerase chain reaction; sALS  sporadic amyotrophic lateral sclerosis; SEDI 
SOD1-exposed-dimer-interface antibody.
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disease affecting
motor neurons of the brain, brainstem, and spinal cord. Approximately 5% of cases are familial ALS
with up to 20% of these caused by mutations in the superoxide dismutase-1 gene (SOD1), a
ubiquitously expressed free-radical scavenging enzyme.1 ALS caused by SOD1 mutations is not
believed to be related to changes in normal enzymatic activity, but is attributed to a gain of toxic
function.2 However, the exact mechanism of SOD1 pathogenesis remains uncertain.
Inheritance patterns for patients with familial ALS can be complicated and the risk to
currently unaffected mutation carriers can be difficult to ascertain. Hence, it is critical to
understand the factors influencing the manifestation of ALS. Over 100 different, mainly mis-
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sense, SOD1 mutations have been identified
in autosomal dominant ALS (http://alsod.
iop.kcl.ac.uk/Als/misc/dataDownload.aspx);
however, only a third of them have good genetic
support for their pathogenic nature (i.e., segre-
gation study). Furthermore, the disease may
present in an apparently recessive or sporadic
manner due to the considerably reduced pen-
etrance of some SOD1 mutations. The most
striking example is the D90A that exhibits both
dominant and recessive modes of inheritance of
ALS. Several families carrying the D90A muta-
tion require homozygosity for disease, and since
loss of SOD1 enzymatic activity has been dis-
counted as a pathologic mechanism, this sug-
gests the presence of modifier genes in the
recessive haplotype that may reduce the toxicity
of the mutant SOD1 protein.3,4
The factors influencing penetrance remain
a mystery and are addressed in this study for
the first time. We describe a novel SOD1 mu-
tation in a Canadian family originating from
the Philippines, present evidence that the
changes in SOD1 alternative splicing underlie
the low penetrance of the mutation, and discuss
the possibility of a similar mechanism for phe-
notypic heterogeneity in other ALS families.
METHODS Subjects. Twelve members of a Filipino family
were recruited at the ALS Clinic, Sunnybrook Health Sciences
Centre, Toronto, Canada, and affected individuals were diag-
nosed with ALS in accordance with revised El Escorial criteria.5
The presence of the SOD1 mutation was assessed in three inde-
pendent datasets. The previously described UK dataset was re-
cruited through the Queen Elizabeth Hospital, Birmingham,
and included 194 patients with sporadic ALS (mean age at onset
58  11; range 18–81 years).6 The Canadian ALS dataset was
recently collected at the Sunnybrook Health Sciences Centre and
included 60 patients with sporadic (mean age at onset 56  11;
range 36–80 years) and 14 patients with familial ALS (mean age
at onset 50  15; range 29–73 years). In addition, 179 unre-
lated neurologically normal Filipino controls (50  5 years of
age) were selected from a cohort of women who participated in
the Cebu Longitudinal Health and Nutrition Study (www.cpc.
unc.edu.projects/cebu). Required consents were obtained from
all study participants in accordance with the respective ethical
review boards.
Genetic analyses. A complete mutation analysis of SOD1 in-
cluding exon/intron boundaries was performed on members of a
Filipino family. The frequency of the G27/P28 mutation was
evaluated using an AvaII restriction assay. The haplotype analysis
was done using genotypes of 15 microsatellite markers (figure 1)
spanning 17.2 Mb on chromosome 21 and harboring the SOD1
locus (from D21S1884 at 21.5 Mb to D21S1255 at 38.7 Mb).
The haplotypes were constructed using the program MERLIN.7
The exonic splicing enhancer sequences were assessed by using
the ESEfinder (http://rulai.cshl.edu/tools/ESE2).8 The cDNAs
were generated from total RNA (1.5 g) of white blood cells or
the gray matter region from lumbar spinal cord using the
StrataScript first strand synthesis kit (Stratagene, CA). Reverse
transcriptase–polymerase chain reaction (RT-PCR) primers were
designed for the 5=-UTR and exon 5 of SOD1. Real-time RT-PCR
was done by using SYBR Green reagent (TaKaRa Mirus Bio, Mad-
ison, WI) on an ABI7500 system (Applied Biosystems, Foster City,
CA). Details of the assays are available on the Neurology® Web site
at www. neurology.org (see table e-1 and appendix e-1).
Protein analyses. For the immunoblotting analysis, samples
of white blood cells and lumbar spinal cord samples from pa-
tients were homogenized in lysis buffer (50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 0.25% Na de-
oxycholate, and 1% NP-40) with protease inhibitor cocktail
(Roche). The protein concentration of tissue extracts was deter-
mined by bicinchoninic acid assay (Sigma) and 2.5 g protein
extracts were separated on 17.5% sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis, followed by transfer onto PVDF
membranes (Millipore). Membranes were blocked with 5%
(w/v) nonfat milk powder in Tris-buffered saline and then
probed with rabbit polyclonal anti-SOD1 (SOD100, 1:1000,
Stressgen) and secondary antibodies (horseradish peroxide-
conjugated anti-rabbit IgG, Amersham). Blots were developed
with enhanced chemiluminescence reagents (Perkin-Elmer) and
digital images were acquired. Blots were re-probed with mouse
monoclonal anti-GAPDH antibody (1:5000, Biodesign) to con-
trol for equal loading. Quantification of band intensity on the
blot was performed by densitometric analysis using ImageJ
(NIH). The expression of SOD1 was normalized to that of
GAPDH and presented as a relative density. SOD1 activity was
measured in erythrocytes from patients with ALS and controls
using a superoxide dismutase activity kit (900-157, Stressgen)
(see supplementary material).
Immunohistochemistry. Sections of 6 m were cut from
formalin-fixed paraffin-embedded sections of autopsied lumbar
spinal cord tissue, and rehydrated through a graded series of
ethanol washes and water, as we have described previously.9 Sec-
tions were labeled with antibodies to phosphorylated neurofila-
ments (SMI31, diluted 1:5,000; Sternberger Monoclonals,
Baltimore, MD) or SOD1-exposed-dimer-interface antibody
(SEDI antibody, diluted 1:500), a previously described rabbit
polyclonal antibody that labels misfolded SOD1.10 For SEDI
antibody, sections were pretreated with 10 mM sodium citrate
buffer (pH 6.0) before labeling. Labeling was detected using the
peroxidase-based Dako EnVision kit with DAB or Permanent
Red as chromogenic substrate. All sections were counterstained
with hematoxylin.
RESULTS Clinical findings. Proband 1078 belongs
to a Canadian family of Filipino ancestry with 20
known family members (figure 1), with samples from
12 individuals of this kindred available for study.
Overall, three family members have been diagnosed
with and died of ALS. The mean age at onset was
55.3  5.1 (range 51–61) years; mean age at death
was 59.7  5.8 (range 55–66) years; and mean dura-
tion was 4.3  1.5 (range 4–6) years. There is no
known history of consanguinity in the family.
Patient 1078 (proband) was diagnosed with ALS
at the Sunnybrook ALS Clinic at age 53. The symp-
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toms began at age 51 when the patient experienced
progressive leg followed by arm weakness. Bulbar
symptoms then followed and the patient died of re-
spiratory failure as a complication of ALS at age 55.
Patient 1078 had predominantly lower motor neu-
ron signs with only mildly brisk reflexes in the upper
limbs. The autopsy result confirmed the diagnosis of
ALS as discussed below.
Patient 3 (the proband’s father) was diagnosed
with ALS at the Sunnybrook ALS Clinic at age 62
and died 4 years later at age 66 (no autopsy was per-
formed). The ALS symptoms began at age 61 and the
disease had a similar course as in patient 1078 with
predominantly lower motor neuron findings, which
began in the legs and then progressed to the arms and
bulbar regions. Patient 5 (the paternal uncle of the
proband) was diagnosed with ALS by a neurologist in
the Philippines at age 54 and died 4 years later at age
58. No additional clinical details are available.
The 11 remaining family members who were
available for the current study are older than 48 years
and report good health. A detailed clinical neurologic
assessment of these family members was performed
by a neurologist, who was blind to genetic status of
Figure 1 Pedigree of an amyotrophic lateral sclerosis (ALS) family with a SOD1 mutation
The pedigree structure of the Filipino family segregating the G27/P28 mutation (del); the asterisk indicates the 12 individuals for whom DNA samples and
genotypes were obtained. Affected individuals are shown as filled symbols and the arrow points to the proband with the homozygous deletion. A slash
indicates deceased persons. Below the DNA number is the age at onset for affected individuals, age at examination, or age at death for unaffected
individuals. Genotypes are shown only for the key individuals to protect family confidentiality. Markers used for haplotype analysis are shown to the left
(founder haplotype is in bold). The inferred haplotype of the proband’s father (no. 3) is reconstructed based on the genotypes of his four children available
for study.
Neurology 72 March 31, 2009 1155
the participants. All clinical examinations were found
to be normal. Hence, none of the living family mem-
bers demonstrate any signs of ALS, including four
individuals older than the mean age at onset (61–85
years old). In addition, the grandparents of the pro-
band died of causes unrelated to ALS at 52, 65, 67,
and 80 years of age as result of stroke or pneumonia.
Genetic analyses. Sequence analysis of the entire open
reading frame of SOD1 was performed on the pro-
band 1078. We detected a novel homozygous
GGACCA-deletion at genomic nucleotide posit-
ion 31957983 according to accession number
NC_000021.7 (Gly27delGGACCA) (figure 2). This
6-bp deletion in exon 2 removes two amino acids
(G27 and P28) in a conserved part of loop II of the
SOD1 protein (G27/P28). No other SOD1 varia-
tions were identified. The G27/P28 was not found
in 179 normal controls of Filipino origin. The muta-
tion is unique to the Filipino family in our ALS data-
set, since it was not observed in any of the 254
unrelated patients from two sporadic cohorts of UK
(n  194) and Canadian (n  60) origin, as well as
in 14 independent Canadian patients with familial
ALS.
The deletion was independently inherited by the
proband’s parents originating from the same Filipino
province (Cagayan). Segregation analysis revealed the
presence of heterozygous G27/P28 mutation in
eight unaffected individuals and enabled the recon-
struction of the genotype of ALS patient 3 (pro-
band’s father) who was an obligate heterozygote,
based on the genotypes of his children: 1078 (ho-
mozygous carrier) and 1103 (wild-type). Haplotype
analysis confirmed this conclusion and excluded
nonpaternity in the family (figure 1). Furthermore, it
showed that the G27/P28 is a single founder muta-
tion, since all carriers inherited a common 1.6 Mb
haplotype harboring SOD1 locus (between markers
D21S263 and D21S262).
Sequencing analysis of SOD1 in the two oldest
heterozygotes (84 and 85 years old) did not reveal
any additional variations; however, the G27/P28
mutation may itself be responsible for the low pen-
etrance. The G27/P28 is predicted to enhance nat-
urally occurring alternative splicing of exon 2 of the
SOD1 mRNA, since it eliminates an exonic enhancer
sequence for the splicing factor SC35, which pro-
motes exon definition (score 4.7 for GACCAGTG-
motif).8 Hence, exon 2 in mutation carriers could be
poorly recognized by the splicing machinery, leading
to its removal from SOD1 mRNA and therefore de-
creasing the expression of the mutant allele.
RT-PCR confirmed the prediction above (figure
3). It was performed on white blood cells from eight
family members with different mutation status (wild-
type, homozygote, and six heterozygotes). Apart
from the full-length SOD1 transcript (444 bp), we
observed two additional fragments. Sequence analy-
sis showed that the 347 bp band corresponds to
SOD1 cDNA without exon 2, while the 277 bp band
represents a transcript without exons 2 and 3. Both
splicing events create a frameshift after exon 1 result-
ing in a premature stop codon. The abundance of the
transcript lacking exons 2 and 3 was similar in all
individuals. In contrast, the expression of the tran-
script without exon 2 was enhanced in mutation carriers
with the highest abundance in the homozygous pro-
band (1:1 ratio between transcripts with and without
exon 2), while this isoform was observed at a much
lower level in the wild-type individual.
In addition, we conducted RT-PCR on lumbar
spinal cord tissues of six unrelated individuals includ-
ing the proband (figure 3A). Again, the highest level
of the transcript without exon 2 was observed in the
Figure 2 Mutation analysis of a Filipino amyotrophic lateral sclerosis (ALS) family
(A) DNA sequence fluorescent chromatogram of the SOD1 G27/P28 deletion observed in family members. (B) Multiple
alignment of the sequence around the G27/P28. The gray highlight indicates areas of conservation (50% of bases in the
alignment matches). The boxed area represents the G27/P28 deletion.
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homozygous carrier, whereas it was barely detected in
all other samples. The isoform lacking both exon 2
and exon 3 was not identified. The results of the
conventional RT-PCR were confirmed by quanti-
tative RT-PCR (figure 3B). Since G27/P28 in-
creases the splicing of exon 2, there is a
concomitant reduction in expression of the full-
length mutant transcript (twice less in the ho-
mozygote than in wild-type).
Protein analyses of SOD1. In order to assess the rela-
tive expression of SOD1 at the protein level, we per-
formed a Western blot analysis (figure 4A). White
blood cells and spinal cord samples from patients
with different mutation status demonstrated consid-
erable downregulation of SOD1 in individuals with
G27/P28 (especially striking in the homozygous
carrier). The splicing isoforms lacking exon 2 would
have a predicted molecular weight of 3.7 kDa and
5.5 kDa; however, no such species were detected in
either blood or spinal cord samples. Quantification
of the band intensities revealed a 30–40% reduction
in SOD1 expression in white blood cells from the
heterozygous G27/P28 family members relative to
wild-type (lanes 1–4 and 7–8 vs lane 5) (figure 4B).
This reduction was even more pronounced in the
homozygote (lane 6 vs lane 5; 8%). The SOD1
level in the spinal cord sample from the homozygous
carrier was 40% less than in the spinal cord sam-
ples of individuals without G27/P28 (lane 9 vs
lanes 10–14). In addition, the SOD1 enzyme activ-
ity was measured in erythrocytes from the homozy-
gous proband, a heterozygous family member, one
patient with sporadic ALS, and two normal controls
(figure e-1). The sample from the homozygous car-
rier demonstrated a reduced activity of SOD1 (by
50% of the control level), and the activity of a
sample from the heterozygous carrier was also re-
duced, but to a lesser extent (by 30% of the control
level).
Immunohistochemistry. The diagnosis of ALS for the
proband was confirmed by neuropathologic analysis
(figure 5). The underlying role of SOD1 in causation
of ALS was supported by the presence of neurofila-
mentous hyaline conglomerate inclusions (HCI).11,12
These inclusions had the typical floccular appearance
of HCIs and were labeled with antibody to phos-
phorylated neurofilaments. In addition, sections
were labeled with SEDI antibody, targeting mis-
folded SOD1.10 The HCIs were consistently labeled
with the SEDI antibody, displaying a patchy appear-
ance within the inclusions. Collectively, these obser-
vations support a diagnosis of ALS caused by mutant
SOD1.
DISCUSSION This is the first report of a SOD1-
linked family of Filipino origin and it would be im-
portant to estimate the mutation prevalence in
Filipino patients with ALS, since the deletion was
independently inherited by the proband’s parents
originating from the Cagayan province. In agree-
ment with a single founder, the extended 1.6 Mb
haplotype around SOD1 is common to all carriers of
G27/P28. The absence of any clinical signs of ALS
in eight heterozygotes and the occurrence of a ho-
mozygous carrier could indicate that G27/P28 is
associated with a recessive mode of inheritance; how-
ever, patient 3 was likely a heterozygote and yet de-
veloped ALS. Nevertheless, the disease in patient 3
was less severe than in the homozygous proband with
ALS onset, delayed by a decade and extended dura-
tion (figure 1). There are several possible explana-
tions for why patient 3 developed ALS, while other
Figure 3 Result of RT-PCR on individuals with different mutation status
(A) The result of conventional reverse transcriptase–polymerase chain reaction (RT-PCR) on
blood samples from members of the Filipino family and on spinal cord tissue of six unrelated
individuals: the homozygote for G27/P28, heterozygote for A4V SOD1, two patients with
sporadic amyotrophic lateral sclerosis (sALS), a patient with Alzheimer disease (AD), and a
patient with corticobasal syndrome (CBD). The arrows point to different SOD1 amplifica-
tion products representing the transcript with all five coding exons (full-length), splice vari-
ant lacking exon 2, and splice variant lacking both exon 2 and 3. The RT-PCR result was
replicated in three independent experiments. (B) The result of quantitative RT-PCR for Fili-
pino family members, including the homozygote (1078), heterozygote (1089), and wild-
type individual (1092). Samples were analyzed in triplicate (error bars represent SD). The
G27/P28 homozygote demonstrated the lowest level of full-length SOD1 expression (left
graph) and the highest level of expression of the transcript without exon 2 (middle graph).
The abundance of the SOD1 fragment lacking both exon 2 and exon 3 was similar in all
three individuals (right graph).
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heterozygotes have not (e.g., male gender as a disease
risk factor13 [figure 1], trans-acting suppressors of al-
ternative splicing, or a second mutation in another
ALS gene). The absence of a sample for patient 3
precludes such an investigation; however, the ongo-
ing collection of Filipino cases could recover similar
families.
The low penetrance of G27/P28 could be ex-
plained by the fact that the deletion enhances alter-
native splicing of exon 2 and consequently reduces
the expression of the mutant allele, which is sup-
ported by the results of RT-PCR and Western blot
(figures 3 and 4). In agreement with these data,
SOD1 activity in the erythrocytes of mutation carri-
ers was considerably reduced compared to the con-
trol samples (figure e-1).
The possibility for the pathologic significance of
the SOD1 transcript lacking exon 2 (or both exon 2
and 3) is diminished by the fact that it was observed
in subjects with and without neurologic diseases (in-
cluding ALS).14,15 Furthermore, these transcripts
containing a premature termination codon are pre-
dicted to encode a protein truncated after exon 1;
however, our result (figure 4) and two independent
studies using different antibodies14,15 failed to detect
such proteins, suggesting either its rapid degradation
or the absence of translation. It was reported that
nonsense-mediated mRNA decay underlies the clear-
ance of SOD1 mRNA with a premature termination
codon in exons 1–4, but not in exon 5.16 This is why
among the reported SOD1 ALS mutations, stop
codon mutations exclusively occur in exon 5. It is
possible that nonsense-mediated decay could be in-
volved in the degradation of the alternatively spliced
SOD1 mRNA, which could be more efficient in spi-
nal cord tissue than in blood cells, since the level of
SOD1 transcript without exon 2 was lower in the
spinal cord (figure 3).
Figure 4 Immunoblotting analysis of SOD1 expression
(A) Western blot with arrow points to the samples from the proband. Protein lysates of white blood cells from family members heterozygous (lanes 1– 4 and
7– 8), wild-type (lane 5), and homozygous (lane 6) for the G27/P28 deletion, and lumbar spinal cord extracts from the G27/P28 homozygote (lane 9),
familial amyotrophic lateral sclerosis (ALS) A4V case (lane 10), two sporadic ALS cases (lanes 11–12), Alzheimer disease case (lane 13), and corticobasal
syndrome case (lane 14) immunoblotted against anti-SOD1 antibody. The membrane was reprobed with anti-GAPDH antibody to show equal loading. (B)
Quantification of SOD1 protein expression based on immunoblotting band intensity (relative density normalized to GAPDH).
Figure 5 Immunohistochemical labeling in motor neurons of the homozygous mutation carrier
Labeling of hyaline conglomerate inclusions (HCI) in patient 1078 carrying the homozygous G27/P28 SOD1 mutation show specificity for SOD1-related
amyotrophic lateral sclerosis. Hematoxylin staining (A) shows floccular appearance of HCI. Labeling of HCIs with phosphorylated neurofilament antibody
(B) and an antibody recognizing misfolded SOD1, SEDI antibody (C). Scale bar  12 m.
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Thus, the enhanced splicing of exon 2 acts as a
natural knock-down of the mutant allele, since half
of the mutant transcript would not be translated. It is
tempting to speculate that a similar mechanism
could play a role in the phenotypic modification of
other ALS kindreds, including the Scandinavian
families with D90A mutation.3,4 Since pedigrees with
D90A have retained a recessive inheritance regardless
of considerable outbreeding, it was suggested that
SOD1-linked variations account for the modifying
effect.4 Indeed, the pathologic mutation could be
part of a particular SOD1 haplotype that includes
polymorphisms affecting splicing elements, the
promoter region, or microRNA target sites and as
a result causing decreased expression of the mutant
allele. In general, SOD1 could be vulnerable to
alternative splicing because the invariant donor
splice site of the first intron has an atypical GC-
motif instead of the GT-motif required for effi-
cient pre-mRNA splicing.17
Over 74% of human genes generate alternative
transcripts with a bias toward genes expressed in the
nervous system.18 Multiple reports have indicated
that splice variants of proteins associated with key
neuropathologies are linked with disease; however,
the current study for the first time suggests a protec-
tive effect of alternative splicing in neurodegenerative
disease. As such, strategies aimed at inducing splicing
may have therapeutic potential by reducing mutant
SOD1 expression. Hence, there is a need for careful
investigation of alternative splicing of SOD1 and
other ALS genes as factors influencing severity or
phenotypic heterogeneity of either sporadic or famil-
ial ALS.
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